Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

  • On October 22, 2013 Shire announced that it had decided to discontinue the construction of its new manufacturing facility in San Diego. Shire will continue to manufacture DERMAGRAFT in its existing facility in La Jolla, and Shire's ability to meet expected future demand for DERMAGRAFT is not impacted by this decision.  Shire is currently assessing possible disposal opportunities in relation to this facility.

  • Share Buy-Back Program

    • In Q4 2012 Shire commenced a share buy-back program, for the purpose of returning funds to shareholders, of up to $500 million, through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying American Depositary Receipts. As of October 22, 2013 Shire had made on-market repurchases totaling 9,807,835 Ordinary Shares at a cost of $299 million (excluding transaction costs).

    BOARD AND COMMITTEE CHANGES

    • On October 23, 2013 Shire announced that Dominic Blakemore will join the Shire Board of Directors effective January 1, 2014.  On joining the Board, Dominic will become a member of the Shire Audit, Compliance & Risk Committee. Dominic's career experience includes finance and strategy roles with global corporations.  He is currently Group Finance Director of Compass Group plc.

    ADDITIONAL INFORMATION

    The following additional information is included in this press release:

    Page Overview of Third Quarter 2013 Financial Results 6 Financial Information 10 Non GAAP Reconciliation 19 Notes to Editors 23 Safe Harbor Statement 24 Explanation of Non GAAP Measures 24 Trade Marks 25

     

    Dial in details for the live conference call  for investors at 14:00 BST / 09:00 ED
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
    (Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
    (Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
    (Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
    Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
    ... Feb. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences ... that on February 2, 2009 it received a letter ... the Company that the Panel has determined to grant ... Capital Market. The Panel granted the Company through ...
    ... CRY ), a biomaterials, medical device and tissue ... end financial results will be released on Thursday, February 19, ... live webcast at 10:00 a.m. Eastern Time, February 19, 2009, ... session hosted by Steven G. Anderson, president and CEO of ...
    ... first kidney-targeted antisense drug for type 2 diabetes enters ... (Nasdaq: ISIS ) announced today it has ... drug that inhibits the production of sodium dependent glucose ... transporter responsible for glucose re-absorption in the kidney. ...
    Cached Biology Technology:Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market 2CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 3Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 4
    (Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
    (Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
    (Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
    Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
    ... promising new class of drug designed to target the ... system, some of the HCV strains being treated exhibited ... team of Florida State University biologists, chemists and biomedical ... identify the drug-resistant HCV strains and the molecular-level mechanisms ...
    ... powerful new ability to engineer the flavor and aroma of ... publishing the most comprehensive deciphering of the beer,s "proteome" ever ... that make beer "beer") appears in ACS, monthly Journal ... say they were inspired to do the research by a ...
    ... has "significant" potential for preventing cardiomyopathy, a form of heart ... with diabetes, scientists have concluded in a new study. Their ... high risk for diabetic cardiomyopathy, appears in ACS, bi-weekly ... and colleagues note that people with diabetes have at least ...
    Cached Biology News:Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
    ...
    Request Info...
    Human RUNX2/CBFA1 MAb (Clone 232902)...
    ... Streptavidin-Horseradish Peroxidase Conjugate, ... to reporter enzyme molecules ... and in situ hybridization ... Blotting & Labeling & ...
    Biology Products: